ArticleOncology letters2020

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.

Shigeo Shimose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.